Earnings summaries and quarterly performance for Currenc Group.
Research analysts covering Currenc Group.
Recent press releases and 8-K filings for CURR.
SCIENTURE Holdings Provides Commercial Update and Q1 2026 Outlook
CURR
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- SCIENTURE Holdings announced significant market access achievements for ARBLI™, including GPO agreements for over 2,500 healthcare institutions and formulary inclusion covering over 100 million lives, aiming to accelerate revenue growth.
- The company reaffirmed its plan to launch REZENOPY™, an opioid overdose emergency treatment, in the second quarter of 2026, targeting a combined US annual losartan and naloxone market of nearly $385 million.
- For Q1 2026, SCIENTURE anticipates continued sequential growth in ARBLI™ prescription volumes and product adoption, alongside improved commercial efficiency.
- SCIENTURE reported a significant balance sheet improvement in Q4 2025, with a cash position of approximately $7.0 million as of December 31, 2025, following a substantial reduction in outstanding debt.
3 days ago
Currenc Group Receives Nasdaq Deficiency Notification
CURR
Delisting/Listing Issues
- Currenc Group Inc. (CURR) received a Nasdaq Annual Meeting Deficiency Letter on January 12, 2026, because it has not held an annual meeting of shareholders within twelve months of its fiscal year end.
- This means the company is no longer in compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G).
- The company has 45 calendar days from January 12, 2026, to submit a plan to regain compliance.
- Currenc has an annual meeting (EGM) scheduled for February 25, 2026, and if Nasdaq accepts this plan, the company may be granted an exception until June 29, 2026, to regain compliance.
- The deficiency letter has no immediate effect on the listing or trading of the company's securities on Nasdaq.
Jan 21, 2026, 2:20 PM
Currenc Group Inc. to hold EGM for Debt-to-Equity Conversion, New Equity Plan, and Auditor Ratification
CURR
Debt Issuance
Executive Compensation
Auditor Change
- Currenc Group Inc. will hold an Extraordinary General Meeting (EGM) to vote on several proposals, including a Debt-to-Equity Conversion to issue 35,653,995 ordinary shares at US$1.53 per share to settle US$54,550,612.30 of aggregate indebtedness owed to Mr. Alexander King Ong Kong and Regal Planet Limited. This conversion is projected to decrease total debt from $126.4 million to $71.8 million and increase shareholders' equity from a deficit of $31.8 million to equity of $22.7 million on a pro forma basis as of June 30, 2025.
- Shareholders will also vote on the adoption of the 2025 Equity Incentive Plan, which proposes a new share reserve of up to 10,000,000 Ordinary Shares and includes an annual evergreen feature to increase the reserve by up to 5% of outstanding shares starting January 1, 2026.
- The EGM agenda includes a proposal to ratify the appointment of MRI Moores Rowland LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
- As of the record date of January 15, 2026, there were 76,611,444 Ordinary Shares outstanding.
Jan 16, 2026, 9:41 PM
Currenc Group Announces Divestment of Controlling Interest in Tranglo
CURR
M&A
Debt Issuance
New Projects/Investments
- Currenc Group Inc. announced the divestment of its 60% controlling interest in Tranglo Sdn. Bhd. to New Margin Holding Limited.
- The transaction is valued at US$400 million, payable in two installments: US$200 million at closing and the remaining US$200 million within 90 days thereafter.
- This divestment is a foundational step in Currenc's strategic transformation to monetize existing businesses, streamline its corporate structure, and accelerate its focus on AI, Web3, and Digital Assets initiatives.
- Currenc intends to use the proceeds from the divestment to reduce its debt, strengthening its financial position.
- The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close following their satisfaction.
Jan 2, 2026, 10:22 PM
Currenc Group Inc. Announces First Half 2025 Financial Results
CURR
Earnings
New Projects/Investments
Demand Weakening
- Currenc Group Inc. announced its financial results for the first half of 2025, reporting a net loss of US$9.5 million and a total EBITDA loss of US$6.2 million.
- Total Revenues, excluding TNG Asia and GEA, were US$18.8 million for the first half of 2025, representing a 10.8% decrease year-over-year, primarily due to a decline in global and Indonesian airtime revenue.
- Total Processing Value (TPV) through Tranglo was US$2.8 billion for the first half of 2025, decreasing by 5.8% year-over-year.
- Operating expenses increased to US$15.1 million for the first half of 2025 from US$11.0 million in the same period of 2024, mainly due to US$4.3 million in incentive shares granted to employees and US$1.5 million for developing new AI product offerings.
- The company plans to deemphasize airtime transfer and reallocate resources and capital to expand its new AI product offerings.
Dec 1, 2025, 10:05 PM
Currenc Group Inc. Announces Q3 2025 Unaudited Financial Results
CURR
Earnings
New Projects/Investments
M&A
- Currenc Group Inc. reported a net profit attributable to the company of US$2.91 million for the third quarter ended September 30, 2025, a significant turnaround from a net loss of US$19.83 million in the same period of 2024. The company's total EBITDA for Q3 2025 was a profit of US$3.6 million.
- Total revenues, excluding divested entities, decreased 3.9% year-over-year to US$10.4 million for Q3 2025, primarily due to lower Indonesian Airtime revenue. This was partly offset by a 54.8% increase in remittance revenue to US$7.0 million, driven by a 10.1% year-over-year increase in Total Processing Value (TPV) to US$1.41 billion through Tranglo.
- The company's gross profit margin improved to 50.8% in Q3 2025 from 27.8% in Q3 2024, largely due to a 37.0% decrease in direct costs of revenue and a significant reduction in total operating expenses to US$0.5 million from US$19.1 million.
- Currenc is strategically shifting focus, deemphasizing lower-margin airtime transfers to reallocate resources towards new AI product offerings, and is progressing with a proposed reverse merger with Animoca Brands.
Nov 10, 2025, 2:29 PM
SCIENTURE Announces Arbli™ Formulary Inclusion, Expanding Coverage
CURR
Product Launch
- SCIENTURE HOLDINGS, INC. announced on November 04, 2025, that Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL, has been added to the formularies of key national payors.
- This inclusion expands access to over 100 million covered lives across the United States through multiple commercial coverage and Medicare supplement plans.
- Arbli™ is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium, targeting a U.S. losartan market that totaled approximately $256 million in annual sales with over 71 million prescriptions as of June 2025.
Nov 4, 2025, 1:05 PM
Currenc Group Announces Proposed Reverse Merger with Animoca Brands
CURR
M&A
New Projects/Investments
- Currenc Group Inc. announced a proposed reverse merger with Animoca Brands Corporation Limited, aiming to create the world's first publicly-listed digital assets conglomerate.
- Upon completion, shareholders of Animoca Brands are expected to collectively own approximately 95% of the resulting entity, while current Currenc shareholders would hold approximately 5%.
- The transaction is anticipated to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
- Currenc intends to divest its existing AI-powered solutions for financial institutions and digital remittance platform to its current shareholders prior to the merger's closing.
Nov 3, 2025, 1:00 PM
Currenc Group Announces Convertible Note Financing
CURR
Debt Issuance
New Projects/Investments
- Currenc Group Inc. has announced an agreement to issue and sell up to $33.0 million in unsecured convertible promissory notes due October 8, 2027.
- An initial $4.4 million of the principal amount has already closed, providing $4.0 million in net proceeds to the company.
- The notes bear interest at 5.00% per annum and include 50% warrant coverage with an exercise price of $1.85 per share.
- The company expects to use the proceeds for general corporate purposes, including working capital and growth initiatives, and may repay existing indebtedness.
Oct 14, 2025, 12:22 PM
Angelini Ventures Leads Investment in Serenis
CURR
New Projects/Investments
Revenue Acceleration/Inflection
- Angelini Ventures led a €12 million follow-on investment in Serenis, a digital mental and physical health company, with CDP Venture Capital as co-lead investor.
- Serenis, founded in 2021, has rapidly expanded its network to over 2,500 licensed professionals, supported over 170,000 people, and serves more than 250 companies through corporate wellbeing programs.
- The company demonstrated strong revenue growth, from €2 million in 2022 to €25 million in 2024, with a run-rate already above €40 million in 2025.
- This investment aims to accelerate Serenis’ innovation in digital care services, strengthen its proprietary technologies, and expand its leadership in delivering solutions to corporate clients.
Oct 3, 2025, 8:01 AM
Quarterly earnings call transcripts for Currenc Group.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more